|
US4450150A
(en)
|
1973-05-17 |
1984-05-22 |
Arthur D. Little, Inc. |
Biodegradable, implantable drug delivery depots, and method for preparing and using the same
|
|
AU597574B2
(en)
|
1986-03-07 |
1990-06-07 |
Massachusetts Institute Of Technology |
Method for enhancing glycoprotein stability
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
ATE243754T1
(de)
|
1987-05-21 |
2003-07-15 |
Micromet Ag |
Multifunktionelle proteine mit vorbestimmter zielsetzung
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
EP1690934A3
(en)
|
1990-01-12 |
2008-07-30 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
ATE300615T1
(de)
|
1990-08-29 |
2005-08-15 |
Genpharm Int |
Transgene mäuse fähig zur produktion heterologer antikörper
|
|
US6770274B1
(en)
|
1990-09-14 |
2004-08-03 |
The General Hospital Corporation |
Viral mutant HSV mediated destruction of neoplastic cells
|
|
CA2405246A1
(en)
|
1990-12-03 |
1992-06-11 |
Genentech, Inc. |
Enrichment method for variant proteins with alterred binding properties
|
|
US5780279A
(en)
|
1990-12-03 |
1998-07-14 |
Genentech, Inc. |
Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
|
|
JP3266311B2
(ja)
|
1991-05-02 |
2002-03-18 |
生化学工業株式会社 |
新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
|
|
US6225447B1
(en)
|
1991-05-15 |
2001-05-01 |
Cambridge Antibody Technology Ltd. |
Methods for producing members of specific binding pairs
|
|
US5871907A
(en)
|
1991-05-15 |
1999-02-16 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
|
US5858657A
(en)
|
1992-05-15 |
1999-01-12 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
|
GB9206422D0
(en)
|
1992-03-24 |
1992-05-06 |
Bolt Sarah L |
Antibody preparation
|
|
US7381803B1
(en)
|
1992-03-27 |
2008-06-03 |
Pdl Biopharma, Inc. |
Humanized antibodies against CD3
|
|
US5855885A
(en)
|
1993-01-22 |
1999-01-05 |
Smith; Rodger |
Isolation and production of catalytic antibodies using phage technology
|
|
US6699468B1
(en)
|
1994-06-23 |
2004-03-02 |
Georgetown University |
Replication-competent herpes simplex virus mediates destruction of neoplastic cells
|
|
US5728379A
(en)
|
1994-06-23 |
1998-03-17 |
Georgetown University |
Tumor- or cell-specific herpes simplex virus replication
|
|
US5585096A
(en)
|
1994-06-23 |
1996-12-17 |
Georgetown University |
Replication-competent herpes simplex virus mediates destruction of neoplastic cells
|
|
US5702892A
(en)
|
1995-05-09 |
1997-12-30 |
The United States Of America As Represented By The Department Of Health And Human Services |
Phage-display of immunoglobulin heavy chain libraries
|
|
US6265150B1
(en)
|
1995-06-07 |
2001-07-24 |
Becton Dickinson & Company |
Phage antibodies
|
|
US5714352A
(en)
|
1996-03-20 |
1998-02-03 |
Xenotech Incorporated |
Directed switch-mediated DNA recombination
|
|
US5824318A
(en)
|
1996-07-24 |
1998-10-20 |
American Cyanamid Company |
Avirulent herpetic viruses useful as tumoricidal agents and vaccines
|
|
EP1500329B1
(en)
|
1996-12-03 |
2012-03-21 |
Amgen Fremont Inc. |
Human antibodies that specifically bind human TNF alpha
|
|
US6057098A
(en)
|
1997-04-04 |
2000-05-02 |
Biosite Diagnostics, Inc. |
Polyvalent display libraries
|
|
US6379674B1
(en)
|
1997-08-12 |
2002-04-30 |
Georgetown University |
Use of herpes vectors for tumor therapy
|
|
EP1053752A1
(en)
|
1998-02-10 |
2000-11-22 |
Yoshitomi Pharmaceutical Industries, Ltd. |
Preparations with controlled release
|
|
CZ302070B6
(cs)
|
1998-04-21 |
2010-09-29 |
Micromet Ag |
Jednoretezcový multifunkcní polypeptid, polynukleotid, vektor obsahující tento polynukleotid, bunka transfekovaná tímto polynukleotidem, prostredek obsahující tento polypeptid, polynukleotid nebo vektor a jejich použití a zpusob identifikace aktiváto
|
|
GB9815909D0
(en)
|
1998-07-21 |
1998-09-16 |
Btg Int Ltd |
Antibody preparation
|
|
GB2344287A
(en)
|
1998-12-03 |
2000-06-07 |
Ferring Bv |
Controlled release pharmaceutical formulation
|
|
EP1141338A4
(en)
|
1998-12-31 |
2002-09-25 |
Arch Dev Corp |
RECOMBINANT HERPES SIMPLEX VIRUS FOR TREATING NEOPLASTIC DISEASES
|
|
US6307024B1
(en)
|
1999-03-09 |
2001-10-23 |
Zymogenetics, Inc. |
Cytokine zalpha11 Ligand
|
|
AU2905199A
(en)
|
1999-03-15 |
2000-10-04 |
Trustees Of The University Of Pennsylvania, The |
Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
|
|
US6764675B1
(en)
|
1999-06-08 |
2004-07-20 |
The Uab Research Foundation |
Herpes simplex virus expressing foreign genes and method for treating cancers therewith
|
|
US6833268B1
(en)
|
1999-06-10 |
2004-12-21 |
Abgenix, Inc. |
Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
|
|
DE60115600T2
(de)
|
2000-01-21 |
2006-07-20 |
Biovex Ltd. |
Virusstämme für die onkolytische behandlung von krebs
|
|
WO2001058479A1
(en)
|
2000-02-08 |
2001-08-16 |
The Penn State Research Foundation |
Immunotherapy using interleukin 13 receptor subunit alpha 2
|
|
CA2441663C
(en)
|
2001-03-27 |
2013-01-22 |
Medigene, Inc. |
Viral vectors and their use in therapeutic methods
|
|
AR036993A1
(es)
|
2001-04-02 |
2004-10-20 |
Wyeth Corp |
Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
|
|
DK1451322T3
(da)
|
2001-11-05 |
2010-02-01 |
Zymogenetics Inc |
Il-21-antagonister
|
|
CA2467633C
(en)
|
2001-12-03 |
2012-03-27 |
Abgenix, Inc. |
Antibody categorization based on binding characteristics
|
|
AU2003280410B8
(en)
|
2002-01-18 |
2009-04-23 |
Zymogenetics, Inc. |
Cytokine receptor zcytor17 multimers
|
|
US7736652B2
(en)
|
2002-03-21 |
2010-06-15 |
The Regents Of The University Of California |
Antibody fusion proteins: effective adjuvants of protein vaccination
|
|
MXPA04012116A
(es)
|
2002-06-07 |
2005-04-19 |
Zymogenetics Inc |
Uso del il-21 en cancer y otras aplicaciones terapeuticas.
|
|
DE60331455D1
(de)
|
2002-10-04 |
2010-04-08 |
Microchips Inc |
Medizinische vorrichtung zur gesteuerten arzneimittelverabreichung sowie herzüberwachung und/oder herzstimulation
|
|
CN1513993A
(zh)
*
|
2002-12-31 |
2004-07-21 |
北京博泰迪生物工程科技开发有限公司 |
中国人基因组cDNA文库白细胞介素21的编码基因序列及其蛋白质的氨基酸序列
|
|
CA2522586C
(en)
|
2003-05-31 |
2017-02-21 |
Micromet Ag |
Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
|
|
US7276478B2
(en)
|
2003-09-25 |
2007-10-02 |
Zymogenetics, Inc. |
Methods of treating autoimmune diseases using IL-21
|
|
DE602004030811D1
(de)
|
2003-10-16 |
2011-02-10 |
Micromet Ag |
Multispezifische deimmunisierte cd3-bindende moleküle
|
|
JP5139800B2
(ja)
|
2004-06-03 |
2013-02-06 |
ノビミューン エスアー |
抗ｃｄ３抗体およびその使用方法
|
|
US7731952B2
(en)
|
2004-06-24 |
2010-06-08 |
New York University |
Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
|
|
CN101208303A
(zh)
|
2005-03-14 |
2008-06-25 |
默克公司 |
Cgrp受体拮抗剂
|
|
AU2006237329B2
(en)
|
2005-04-18 |
2012-04-12 |
Novo Nordisk A/S |
IL-21 variants
|
|
RU2494107C2
(ru)
|
2005-05-09 |
2013-09-27 |
Оно Фармасьютикал Ко., Лтд. |
Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
|
|
AU2006341398B9
(en)
|
2005-11-28 |
2012-02-02 |
Zymogenetics, Inc. |
IL-21 receptor antagonists
|
|
AU2006340750B2
(en)
|
2005-11-28 |
2013-03-07 |
Zymogenetics, Inc. |
IL-21 antagonists
|
|
TW200745163A
(en)
|
2006-02-17 |
2007-12-16 |
Syntonix Pharmaceuticals Inc |
Peptides that block the binding of IgG to FcRn
|
|
EA200802289A1
(ru)
|
2006-05-08 |
2009-04-28 |
Филоджен Спа |
Направляемые к мишени антителами цитокины для терапии
|
|
AU2007310777A1
(en)
|
2006-10-26 |
2008-05-02 |
Novo Nordisk A/S |
IL-21 variants
|
|
CA2671665A1
(en)
|
2006-12-21 |
2008-06-26 |
Novo-Nordisk A/S |
Interleukin-21 variants with altered binding to the il-21 receptor
|
|
CN101230334B
(zh)
|
2007-01-22 |
2011-06-01 |
北京奥源和力生物技术有限公司 |
单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
|
|
CN101230335B
(zh)
|
2007-01-22 |
2010-08-11 |
北京奥源和力生物技术有限公司 |
单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
|
|
RS53008B2
(sr)
|
2007-04-03 |
2022-12-30 |
Amgen Res Munich Gmbh |
Interspecijski specifičan cd3-epsilon vezujući domen
|
|
WO2008119565A2
(en)
|
2007-04-03 |
2008-10-09 |
Micromet Ag |
Cross-species-specific binding domain
|
|
NZ580700A
(en)
|
2007-04-19 |
2012-01-12 |
Dong A Pharm Co Ltd |
A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
|
|
EP3103813A1
(en)
|
2007-12-07 |
2016-12-14 |
ZymoGenetics, Inc. |
Anti-human il-21 monoclonal antibodies
|
|
WO2009114335A2
(en)
|
2008-03-12 |
2009-09-17 |
Merck & Co., Inc. |
Pd-1 binding proteins
|
|
EP2268668A1
(en)
|
2008-04-17 |
2011-01-05 |
Ablynx N.V. |
Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
|
|
JP6126782B2
(ja)
|
2008-10-01 |
2017-05-10 |
アムゲン リサーチ （ミュンヘン） ゲーエムベーハー |
異種間特異的ｐｓｍａ×ｃｄ３二重特異性単鎖抗体
|
|
EP2406282A1
(en)
*
|
2009-03-11 |
2012-01-18 |
Novo Nordisk A/S |
Interleukin-21 variants having antagonistic binding to the il-21 receptor
|
|
PE20120591A1
(es)
|
2009-04-02 |
2012-05-23 |
Roche Glycart Ag |
Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
|
|
JP5816170B2
(ja)
|
2009-06-26 |
2015-11-18 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
|
|
ES2534085T3
(es)
|
2009-08-17 |
2015-04-17 |
Roche Glycart Ag |
Inmunoconjugados dirigidos
|
|
CA2776241A1
(en)
|
2009-10-30 |
2011-05-05 |
Novozymes Biopharma Dk A/S |
Albumin variants
|
|
CA3083324A1
(en)
|
2010-03-05 |
2011-09-09 |
The Johns Hopkins University |
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
|
|
CN103347893A
(zh)
|
2010-11-01 |
2013-10-09 |
诺维信生物制药丹麦公司 |
白蛋白变体
|
|
MX2013009151A
(es)
|
2011-02-10 |
2013-08-29 |
Roche Glycart Ag |
Inmunoterapia mejorada.
|
|
US20140038285A1
(en)
|
2011-03-11 |
2014-02-06 |
Amgen Inc. |
Method of correlated mutational analysis to improve therapeutic antibodies
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
RU2650784C2
(ru)
|
2011-05-05 |
2018-04-17 |
Альбумедикс А/С |
Варианты альбумина
|
|
EP2723380B1
(en)
|
2011-06-24 |
2019-08-21 |
Stephen D. Gillies |
Light chain immunoglobulin fusion proteins and methods of use thereof
|
|
US20130028882A1
(en)
|
2011-07-07 |
2013-01-31 |
Humanitas Technology, LLC |
Antiviral compositions and methods of their use
|
|
ES2704632T3
(es)
|
2011-09-08 |
2019-03-19 |
Univ New York |
Virus de herpes simplex oncolítico y sus usos terapéuticos
|
|
SG10201603411WA
(en)
*
|
2011-10-28 |
2016-07-28 |
Teva Pharmaceuticals Australia Pty Ltd |
Polypeptide constructs and uses thereof
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
EP2780364A2
(en)
|
2011-11-18 |
2014-09-24 |
Eleven Biotherapeutics, Inc. |
Proteins with improved half-life and other properties
|
|
WO2013096732A2
(en)
|
2011-12-23 |
2013-06-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of treating or preventing viral diseases by blocking interleukin-21
|
|
US9447160B2
(en)
|
2012-01-19 |
2016-09-20 |
University Of Miami |
Compositions, methods and kits for treatment of cancer and autoimmune diseases
|
|
WO2013135896A1
(en)
|
2012-03-16 |
2013-09-19 |
Novozymes Biopharma Dk A/S |
Albumin variants
|
|
CN110563850A
(zh)
|
2012-04-30 |
2019-12-13 |
比奥孔有限公司 |
靶向/免疫调节性融合蛋白及其制造方法
|
|
WO2013169734A1
(en)
|
2012-05-07 |
2013-11-14 |
Amgen Inc. |
Anti-erythropoietin antibodies
|
|
WO2013169693A1
(en)
*
|
2012-05-09 |
2013-11-14 |
Bristol-Myers Squibb Company |
Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
|
|
AR092044A1
(es)
|
2012-08-07 |
2015-03-18 |
Roche Glycart Ag |
Inmunoterapia mejorada
|
|
MX2015005363A
(es)
|
2012-11-08 |
2015-11-06 |
Novozymes Biopharma Dk As |
Variantes de albumina.
|
|
WO2014139468A1
(en)
|
2013-03-15 |
2014-09-18 |
Admark Healthcare, Llc |
Fusion protein molecules and method of use
|
|
JP6742903B2
(ja)
|
2013-05-02 |
2020-08-19 |
アナプティスバイオ インコーポレイティッド |
プログラム死−１（ｐｄ−１）に対する抗体
|
|
WO2015000585A1
(en)
*
|
2013-07-02 |
2015-01-08 |
Walter Sebald |
Muteins of cytokines of the gamma-chain receptor family conjugated to a non-protein group
|
|
EP3019531A4
(en)
|
2013-07-11 |
2017-03-15 |
The California Institute for Biomedical Research |
Immunoglobulin fusion proteins and compositions thereof
|
|
MY184154A
(en)
|
2013-12-12 |
2021-03-23 |
Shanghai hengrui pharmaceutical co ltd |
Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
SG10201900002QA
(en)
|
2014-01-24 |
2019-02-27 |
Dana Farber Cancer Institue Inc |
Antibody molecules to pd-1 and uses thereof
|
|
WO2015117930A1
(en)
|
2014-02-06 |
2015-08-13 |
F. Hoffmann-La Roche Ag |
Interleukine 10 immunoconjugates
|
|
PT3107573T
(pt)
|
2014-02-19 |
2019-01-10 |
Merck Patent Gmbh |
Imunoterapia com il-12 visada ao cancro
|
|
HUE051676T2
(hu)
|
2014-04-08 |
2021-03-29 |
Boston Pharmaceuticals Inc |
Il-21-re specifikus kötõ molekulák és alkalmazásaik
|
|
CN104403004B
(zh)
|
2014-11-24 |
2017-10-13 |
苏州丁孚靶点生物技术有限公司 |
抗体‑干扰素异二聚体的制备和用途
|
|
EP3875152B1
(en)
|
2014-12-15 |
2024-04-10 |
Washington University |
Compositions and methods for targeted cytokine delivery
|
|
AU2015367224B2
(en)
|
2014-12-19 |
2020-12-10 |
Monash University |
IL-21 antibodies
|
|
EP3233914A1
(en)
|
2014-12-19 |
2017-10-25 |
Mabtech Ab |
Composition, kit and method for inhibition of il-21 mediated activation of human cells
|
|
KR20160113452A
(ko)
|
2015-03-20 |
2016-09-29 |
(주)엘지하우시스 |
진공 단열재용 심재 및 진공단열재
|
|
WO2017019846A1
(en)
|
2015-07-30 |
2017-02-02 |
Macrogenics, Inc. |
Pd-1-binding molecules and methods use thereof
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究（慕尼黑）公司 |
Egfrviii及cd3抗體構築體
|
|
EP3328377A4
(en)
|
2015-07-31 |
2019-03-13 |
Tarveda Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR IMMUNE ONCOLOGY THERAPIES
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
EA039859B1
(ru)
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究（慕尼黑）公司 |
Ｄｌｌ３及ｃｄ３抗體構築體
|
|
KR102055396B1
(ko)
|
2015-08-11 |
2019-12-12 |
우시 바이올로직스 (케이만) 인코포레이티드 |
신규한 항-pd-1 항체
|
|
CN114605548A
(zh)
|
2015-09-01 |
2022-06-10 |
艾吉纳斯公司 |
抗-pd-1抗体及其使用方法
|
|
CR20180151A
(es)
|
2015-10-02 |
2018-05-25 |
Hoffmann La Roche |
Antcuierpos anti-pd1 y métodos de uso
|
|
EP3370768B9
(en)
|
2015-11-03 |
2022-03-16 |
Janssen Biotech, Inc. |
Antibodies specifically binding pd-1 and their uses
|
|
US11702477B2
(en)
|
2015-11-06 |
2023-07-18 |
Orionis Biosciences BV |
Bi-functional chimeric proteins and uses thereof
|
|
JP7126941B2
(ja)
|
2015-12-22 |
2022-08-29 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ
|
|
EP3778881A1
(en)
|
2016-01-08 |
2021-02-17 |
Replimune Limited |
Modified oncolytic virus
|
|
WO2017123643A1
(en)
|
2016-01-11 |
2017-07-20 |
Flagship Pioneering, Inc. |
Methods and compositions for modulating thymic function
|
|
EP3411404B1
(en)
|
2016-02-03 |
2022-11-09 |
Amgen Research (Munich) GmbH |
Psma and cd3 bispecific t cell engaging antibody constructs
|
|
CN116063544A
(zh)
|
2016-02-03 |
2023-05-05 |
安进研发（慕尼黑）股份有限公司 |
Bcma和cd3双特异性t细胞接合抗体构建体
|
|
CA3011374A1
(en)
|
2016-02-05 |
2017-08-10 |
Washington University |
Compositions and methods for targeted cytokine delivery
|
|
US11001631B2
(en)
|
2016-02-05 |
2021-05-11 |
Orionis Biosciences BV |
Clec9A binding agents
|
|
CA3017813C
(en)
|
2016-03-17 |
2021-12-07 |
Oslo Universitetssykehus Hf |
Fusion proteins targeting tumour associated macrophages for treating cancer
|
|
WO2017165464A1
(en)
|
2016-03-21 |
2017-09-28 |
Elstar Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
MY210545A
(en)
|
2016-04-01 |
2025-09-30 |
Kite Pharma Inc |
Chimeric receptors to flt3 and methods of use thereof
|
|
KR102211838B1
(ko)
|
2016-04-22 |
2021-02-03 |
임비라 컴퍼니 리미티드 |
암치료용 종양 용해성 단순 헤르페스 바이러스(oHSV) 절대 벡터 및 그 구조체의 구조
|
|
RU2021127872A
(ru)
|
2016-06-30 |
2021-11-09 |
Онкорус, Инк. |
Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов
|
|
RU2656181C1
(ru)
|
2016-07-13 |
2018-05-31 |
Закрытое Акционерное Общество "Биокад" |
Анти-pd-1-антитела, способ их получения и способ применения
|
|
JP7200104B2
(ja)
|
2016-08-01 |
2023-01-06 |
ヴァイロジン バイオテック カナダ リミテッド |
免疫系刺激分子を発現する腫瘍溶解性単純ヘルペスウイルスベクター
|
|
KR101928981B1
(ko)
|
2016-09-02 |
2018-12-13 |
고려대학교 산학협력단 |
항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물
|
|
AU2017328309B2
(en)
|
2016-09-14 |
2020-10-15 |
Beijing Hanmi Pharm. Co., Ltd. |
Antibody specifically binding to PD-1 and functional fragment thereof
|
|
EP4450616A3
(en)
|
2016-09-21 |
2025-01-01 |
Cstone Pharmaceuticals |
The novel monoclonal antibodies to programmed death 1 (pd-1)
|
|
AU2017331275A1
(en)
|
2016-09-23 |
2019-05-16 |
Oncosec Medical Incorporated |
Modulating responses to checkpoint inhibitor therapy
|
|
HUE057559T2
(hu)
|
2016-11-02 |
2022-06-28 |
Jounce Therapeutics Inc |
PD-1 elleni antitestek és alkalmazásaik
|
|
GB201700350D0
(en)
|
2017-01-09 |
2017-02-22 |
Replimune Ltd |
Altered virus
|
|
CN107082812B
(zh)
|
2017-03-29 |
2018-11-13 |
上海科医联创生物科技有限公司 |
一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
|
|
RU2761377C2
(ru)
|
2017-04-03 |
2021-12-07 |
Ф. Хоффманн-Ля Рош Аг |
Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15
|
|
US20210017247A1
(en)
|
2017-07-03 |
2021-01-21 |
Torque Therapeutics, Inc. |
Fusion Molecules Targeting Immune Regulatory Cells and Uses Thereof
|
|
WO2019173832A2
(en)
|
2018-03-09 |
2019-09-12 |
AskGene Pharma, Inc. |
Novel cytokine prodrugs
|
|
US20210024631A1
(en)
|
2018-03-28 |
2021-01-28 |
Orionis Biosciences, Inc. |
Bi-functional proteins and construction thereof
|
|
CA3095920A1
(en)
|
2018-04-10 |
2019-10-17 |
Amgen Inc. |
Chimeric receptors to dll3 and methods of use thereof
|
|
EP3806889A4
(en)
|
2018-06-18 |
2022-07-13 |
Anwita Biosciences, Inc. |
CYTOKI FUSION PROTEINS AND USES THEREOF
|
|
JP2022502443A
(ja)
|
2018-09-28 |
2022-01-11 |
ピエール、ファーブル、メディカマン |
癌の処置のための新規な免疫サイトカイン
|
|
BR112021012027A2
(pt)
|
2018-12-21 |
2021-11-03 |
Ose Immunotherapeutics |
Molécula bifuncional direcionada contra pd-1 humano
|